公开(公告)号：JP2009256360A

公开(公告)日：2009-11-05

申请号：JP2009148236

申请日：2009-06-23

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： LIN NAN-HORNG ,  HE YUN ,  HOLLADAY MARK W ,  RYTHER KEITH ,  LI YIHONG ,  BAI HAO

IPC: C07D401/12 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/465 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61P25/00 ,  A61P43/00 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14

CPC classification number: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

Abstract: PROBLEM TO BE SOLVED: To provide a compound controlling synapse transmission in a neuron nicotinic cholinergic channel receptor, an intermediate for the synthesis of the compound, and a method for preparing a compound represented by formula (I) using the intermediate. SOLUTION: This compound is 5-(5,5-dimethyl-1,3-hexadienyl)-6-chloro-3-(2-(R)-pyrrolidinylmethoxy)pyridine or its pharmaceutically permissible salt in a 3-pyridyloxymethyl heterocyclic ether compound represented by formula (I). COPYRIGHT: (C)2010,JPO&INPIT

Abstract translation: 待解决的问题：提供控制神经元烟碱胆碱通道受体中的突触传递的化合物，用于合成化合物的中间体，以及使用该中间体制备由式（I）表示的化合物的方法。 解决方案：该化合物是5-（5,5-二甲基-1,3-己二烯基）-6-氯-3-（2-（R） - 吡咯烷基甲氧基）吡啶或其药学上允许的盐，在3-吡啶氧基甲基 由式（I）表示的杂环醚化合物。 版权所有（C）2010，JPO＆INPIT

公开(公告)号：JP2007302691A

公开(公告)日：2007-11-22

申请号：JP2007187127

申请日：2007-07-18

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： HOLLADAY MARK W ,  LIN NAN-HORNG ,  RYTHER KEITH B ,  HE YUN

IPC: C07D401/12 ,  A61K31/00 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P1/00 ,  A61P9/12 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/28 ,  A61P25/30 ,  A61P27/02 ,  A61P43/00 ,  C07D403/12 ,  C07D417/12

CPC classification number: C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: PROBLEM TO BE SOLVED: To provide a neuron nicotinic cholinergic compound selectively useful for the control of synapse transmission and provide a pharmaceutical composition containing the compound. SOLUTION: The invention relates to a new 3-pyridyloxymethyl heterocyclic ether of formula (I) and a pharmaceutical composition containing the compound in combination with a pharmacologically allowable carrier. In the formula, * is a chiral center; n is an integer selected from 1, 2 and 3; X is oxygen or sulfur; R 1 is hydrogen, allyl or a 1-6C alkyl; R 2 is hydrogen or CH2OH, CH2F, CH2CN or the like, when n=2; and A is methylene or ethylene which may be substituted with an alkyl group. COPYRIGHT: (C)2008,JPO&INPIT

Abstract translation: 待解决的问题：提供可选择性地用于控制突触传递的神经元烟碱性胆碱能化合物，并提供含有该化合物的药物组合物。 解决方案：本发明涉及式（I）的新的3-吡啶氧基甲基杂环醚和含有与药理学上允许的载体组合的化合物的药物组合物。 在公式中，*是手性中心; n是选自1,2和3的整数; X是氧或硫; R 1是氢，烯丙基或1-6C烷基; 当n = 2时，R SP 2是氢或CH 2 OH，CH 2 F，CH 2 CN等; 并且A是可被烷基取代的亚甲基或亚乙基。 版权所有（C）2008，JPO＆INPIT

公开(公告)号：CA2315117C

公开(公告)日：2011-03-15

申请号：CA2315117

申请日：1998-12-18

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  ABREO MELWYN A ,  GUNN DAVID E ,  LIN NAN-HORNG ,  GARVEY DAVID S ,  RYTHER KEITH ,  LEBOLD SUZANNE A ,  ELLIOTT RICHARD L ,  HE YUN ,  WASICAK JAMES T ,  BAI HAO ,  DART MICHAEL J ,  EHRLICH PAUL P ,  LI YIHONG ,  KINCAID JOHN F ,  SCHKERYANTZ JEFFREY M ,  LYNCH JOHN K

IPC: C07D401/12 ,  A61K31/40 ,  A61K31/425 ,  A61K31/427 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61P25/00 ,  A61P25/22 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D403/12 ,  C07D417/12 ,  C07D455/02 ,  C07D487/04

Abstract: Novel compounds having formulas (I), (II) or (III) or pharmaceutically-acceptable salts or prodrugs thereof, which are useful for controlling synaptic transmission; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to controlling synaptic transmission in human or veterinary patients.

公开(公告)号：CA2256022C

公开(公告)日：2008-07-29

申请号：CA2256022

申请日：1997-06-04

Applicant: ABBOTT LAB

Inventor： LIN NAN-HORNG ,  HOLLADAY MARK W ,  RYTHER KEITH ,  BAI HAO ,  HE YUN ,  LI YIHONG

IPC: C07D409/14 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/465 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/497 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61P25/00 ,  A61P43/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/14 ,  C07D417/14

Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds of formula (I) or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. Key intermediates and processes using this key intermediates to produce compounds of formula (I) with the variables defined in the specification are also described.

公开(公告)号：DE69730229D1

公开(公告)日：2004-09-16

申请号：DE69730229

申请日：1997-06-04

Applicant: ABBOTT LAB

Inventor： LIN NAN-HORNG ,  HE YUN ,  HOLLADAY W ,  RYTHER KEITH ,  LI YIHONG ,  BAI HAO

IPC: A61K31/44 ,  A61K31/4427 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/465 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61P25/00 ,  A61P43/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14

Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission.

公开(公告)号：PT846114E

公开(公告)日：2002-05-31

申请号：PT96914786

申请日：1996-05-28

Applicant: ABBOTT LAB

Inventor： LIN NAN-HORNG ,  RYTHER KEITH B ,  HE YUN ,  HOLLADAY MARY W

IPC: A61K31/00 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P25/00 ,  A61P25/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds having formula (I), wherein * is a chiral center and n, X, R , R , A andB are specifically defined, which are useful in controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions therof; and use of said compositions to selectively control synaptic transmission in mammals.

公开(公告)号：DE69617701D1

公开(公告)日：2002-01-17

申请号：DE69617701

申请日：1996-05-28

Applicant: ABBOTT LAB

Inventor： HOLLADAY W ,  LIN NAN-HORNG ,  RYTHER B ,  HE YUN

IPC: A61K31/00 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P25/00 ,  A61P25/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds having formula (I), wherein * is a chiral center and n, X, R , R , A andB are specifically defined, which are useful in controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions therof; and use of said compositions to selectively control synaptic transmission in mammals.

公开(公告)号：DK0717741T3

公开(公告)日：2001-08-20

申请号：DK94931741

申请日：1994-08-30

Applicant: ABBOTT LAB

Inventor： LIN NAN-HORNG ,  HE YUN ,  ELLIOTT RICHARD L ,  CHORGHADE MUKUND S ,  WITTENBERGER STEVEN J ,  BUNNELLE WILLIAM H ,  NARAYANAN BIKSHANDAR A ,  SINGAM PULLA R ,  ESCH THOMAS K J ,  BEER DIETER O ,  WITZIG CHRISTIAN C ,  HERZIG THOMAS C ,  RAO ALLA V RAMA

IPC: C07D413/04 ,  C07D207/09

Abstract: A novel process for preparing enantiomerically-pure 3-methyl-5-(1-(C1-C3-alkyl)-2-pyrrolidinyl)isoxazole in high yield, wherein a protected pyrrolidine or 2-oxo-pyrrolidine starting material is reacted with a suitable organic anion and a resulting beta-keto oxime intermediate is cyclized and dehydrated, as well as intermediates useful in the preparation thereof.

公开(公告)号：CA2315117A1

公开(公告)日：1999-07-01

申请号：CA2315117

申请日：1998-12-18

Applicant: ABBOTT LAB

Inventor： HE YUN ,  LEBOLD SUZANNE A ,  ELLIOTT RICHARD L ,  BAI HAO ,  DART MICHAEL J ,  WASICAK JAMES T ,  KINCAID JOHN F ,  GARVEY DAVID S ,  LI YIHONG ,  RYTHER KEITH ,  HOLLADAY MARK W ,  EHRLICH PAUL P ,  ABREO MELWYN A ,  GUNN DAVID E ,  LIN NAN-HORNG ,  SCHKERYANTZ JEFFREY M ,  LYNCH JOHN K

IPC: A61K31/427 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61P25/00 ,  A61P25/22 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D455/02 ,  C07D487/04 ,  A61K31/40 ,  A61K31/425 ,  A61K31/44 ,  A61K31/47 ,  A61K31/50 ,  A61K31/505

Abstract: Novel compounds having formulas (I), (II) or (III) or pharmaceuticallyacceptable salts or prodrugs thereof, which are useful for controlling synaptic transmission; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to controlling synaptic transmission in human or veterinary patients.

公开(公告)号：MX9709721A

公开(公告)日：1998-07-31

申请号：MX9709721

申请日：1997-12-05

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  LIN NAN-HORNG ,  RYTHER KEITH B ,  HE YUN

IPC: A61K31/00 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P25/00 ,  A61P25/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: Compuestos de éter eterocíclico de 3-pirodiloximetilo nivedosos que tienen la Formula (I), en donde * es un centro quiral, y n, X, R1, R2, A y B se definen específicamente, los cuales son utiles para controlar la transmicion sináptica química; composiciones farmacéuticas terapéuticamente efectivas de los mismos; y el uso de estas composiciones para controlar de una manera selectiva la transmision sináptica en mamiferos.